SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-07-29
Accession Number: 0001013762-24-002165
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000101376224002165/ea020832402ex1-1_synergy.htm

Chunk 9 of 15
Word Count: 1377
Character Count: 8653

Document Content:

national securities exchange on which any class of securities of the Company is listed; provided, that any information or documents available on the Commission’s Electronic Data Gathering, Analysis and Retrieval System shall be considered furnished for purposes of this Section 5(a)(xiii). (xiv) The Company hereby agrees to engage and maintain, at its expense, a registrar and transfer agent for the Common Stock (if other than the Company). The Company hereby agrees to use its reasonable best efforts to obtain approval to list the Shares and the Underwriter Warrant Shares on the Nasdaq. (xvi) The Company hereby agrees not to take, directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Shares.

Conditions of the Underwriter’s Obligations. The
respective obligations of the several Underwriters hereunder to purchase the Shares are subject to the accuracy, as of the date hereof
and at all times through the Closing Date, and on each Option Closing Date (as if made on the Closing Date or such Option Closing Date,
as applicable), of and compliance with all representations, warranties and agreements of the Company contained herein, the performance
by the Company of its obligations hereunder and the following additional conditions:

If filing of the Final Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, is required under the
Securities Act or the Rules and Regulations, the Company shall have filed the Final Prospectus (or such amendment or supplement) or such
Issuer Free Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8)
or 164(b) under the Securities Act); the Registration Statement shall remain effective; no stop order suspending the effectiveness of
the Registration Statement or any part thereof, any Rule 462 Registration Statement, or any amendment thereof, nor suspending or preventing
the use of the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus shall have
been issued; no proceedings for the issuance of such an order shall have been initiated or threatened by the Commission; any request
of the Commission or the Representative for additional information (to be included in the Registration Statement, the Time of Sale Disclosure
Package, any Prospectus, the Final Prospectus, any Issuer Free Writing Prospectus or otherwise) shall have been complied with to the
satisfaction of the Representative.

The Shares and the Underwriter Warrant Shares shall be approved for listing on the Nasdaq, subject to official notice of issuance and
evidence of satisfactory distribution.

FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.

(d) The Representative shall not have reasonably determined, and advised the Company, that the Registration Statement, the Time of Sale
Disclosure Package, any Prospectus, the Final Prospectus, or any amendment thereof or supplement thereto, or any Issuer Free Writing Prospectus,
contains an untrue statement of fact which, in the reasonable opinion of the Representative, is material, or omits to state a fact which,
in the reasonable opinion of the Representative, is material and is required to be stated therein or necessary to make the statements
therein not misleading.

On or after the date hereof (i) no downgrading shall have occurred in the rating accorded any of the Company’s securities by any
“nationally recognized statistical organization,” as that term is defined by the Commission for purposes of Rule 436(g)(2)
under the Securities Act, and (ii) no such organization shall have publicly announced that it has under surveillance or review, with
possible negative implications, its rating of any of the Company’s securities.

On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representative, for the benefit of the Underwriters,
the opinion and negative assurance letters of Nelson Mullins Riley & Scarborough LLP , counsel to the Company, each dated the Closing
Date or the Option Closing Date, as applicable, and addressed to the Underwriters, in form and substance reasonably satisfactory to the
Representative.

Omitted.

On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representative, for the benefit of the Underwriters,
the negative assurance letter of Loeb & Loeb LLP, counsel to the Underwriters, dated the Closing Date or the Option Closing Date,
as applicable, and addressed to the Underwriters, in form and substance reasonably satisfactory to Representative.

The Representative, for the benefit of the Underwriters, shall have received a letter of RBSM LLP, on the date hereof and on the Closing
Date and on each Option Closing Date, addressed to the Underwriters, confirming that they are independent public accountants within the
meaning of the Securities Act and are in compliance with the applicable requirements relating to the qualifications of accountants under
Rule 2-01 of Regulation S-X of the Commission, and confirming, as of the date of each such letter (or, with respect to matters involving
changes or developments since the respective dates as of which specified financial information is given in the Registration Statement,
the Time of Sale Disclosure Package and the Final Prospectus, as of a date not prior to the date hereof or more than five days prior
to the date of such letter), the conclusions and findings of said firm with respect to the financial information and other matters required
by the Underwriters.

On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representative, for the benefit of the Underwriters,
a certificate, dated the Closing Date and on each Option Closing Date and addressed to the Underwriters, signed by the chief executive
officer and the chief financial officer of the Company, in their capacity as officers of the Company, to the effect that:

The representations and warranties of the Company in this Agreement that are qualified by materiality or by reference to any Material
Adverse Effect are true and correct in all respects, and all other representations and warranties of the Company in this Agreement are
true and correct, in all material respects, as if made at and as of the Closing Date and on the Option Closing Date, and the Company
has complied with all the agreements and satisfied all the conditions on its part required to be performed or satisfied at or prior to
the Closing Date or on the Option Closing Date, as applicable;

No stop order or other order (A) suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof,
(B) suspending the qualification of the Shares for offering or sale, or (C) suspending or preventing the use of the Time of Sale Disclosure
Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus, has been issued, and no proceeding for that purpose
has been instituted or, to their knowledge, is contemplated by the Commission or any state or regulatory body; and

(iii)
There has been no occurrence of any event resulting or reasonably likely to result in a Material Adverse Effect during the period from
and after the date of this Agreement and prior to the Closing Date or on the Option Closing Date, as applicable.

On or before the date hereof, the Representative shall have received duly executed lock-up agreement (each a “Lock-Up Agreement”)
in the form set forth on Exhibit A hereto, by and between the Representative and each of the parties specified in Schedule

The Company shall have furnished to the Underwriters and their counsel such additional documents, certificates and evidence as the Representative
or its counsel may have reasonably requested.

any condition specified in this Section 6 shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated
by the Representative by notice to the Company at any time at or prior to the Closing Date or on the Option Closing Date, as applicable,
and such termination shall be without liability of any party to any other party, except that Section 5(a)(viii), Section 9 and Section
10 shall survive any such termination and remain in full force and effect.

Indemnification and Contribution.